RhumbLine Advisers
CRDF icon

RhumbLine Advisers’s Cardiff Oncology CRDF Stock Holding History

RhumbLine Advisers’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.1K Sell
30,064
-43,832
-59% -$69.6K ﹤0.01% 3723
2026
Q1 		$120K Sell
73,896
-4,493
-6% -$9.23K ﹤0.01% 3332
2025
Q4 		$220K Sell
78,389
-8,867
-10% -$20.6K ﹤0.01% 3136
2025
Q3 		$180K Buy
87,256
+2,497
+3% +$6.9K ﹤0.01% 3278
2025
Q2 		$267K Buy
84,759
+21,617
+34% +$65.9K ﹤0.01% 3066
2025
Q1 		$198K Buy
63,142
+9,970
+19% +$39.4K ﹤0.01% 3106
2024
Q4 		$231K Buy
53,172
+10,290
+24% +$32.2K ﹤0.01% 3116
2024
Q3 		$114K Sell
42,882
-3,111
-7% -$7.35K ﹤0.01% 3463
2024
Q2 		$102K Buy
+45,993
New +$173K ﹤0.01% 3513
2022
Q2 		– Sell
-46,290
Closed -$115K – 3121
2022
Q1 		$115K Sell
46,290
-294
-0.6% -$1.04K ﹤0.01% 2861
2021
Q4 		$280K Sell
46,584
-1,066
-2% -$6.35K ﹤0.01% 2726
2021
Q3 		$317K Buy
47,650
+1,960
+4% +$12.3K ﹤0.01% 2744
2021
Q2 		$304K Buy
+45,690
New +$388K ﹤0.01% 2782
2017
Q2 		– Sell
-516
Closed -$43K – 2929
2017
Q1 		$43K Buy
516
+170
+49% +$23.1K ﹤0.01% 2827
2016
Q4 		$52K Sell
346
-207
-37% -$48.3K ﹤0.01% 2826
2016
Q3 		$179K Buy
553
+9
+2% +$3.28K ﹤0.01% 2710
2016
Q2 		$177K Buy
544
+153
+39% +$52.7K ﹤0.01% 2800
2016
Q1 		$131K Buy
391
+14
+4% +$4.76K ﹤0.01% 2845
2015
Q4 		$147K Buy
377
+59
+19% +$23.1K ﹤0.01% 2883
2015
Q3 		$130K Buy
318
+36
+13% +$18.8K ﹤0.01% 2901
2015
Q2 		$206K Buy
+282
New +$200K ﹤0.01% 2875

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

RhumbLine Advisers's CRDF Position: Q2 2026 in Review

RhumbLine Advisers reduced its Cardiff Oncology (CRDF) stake by 59% in Q2 2026, selling an estimated $69.6K and leaving 30,064 shares worth $39.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3723.

RhumbLine Advisers first reported a position in CRDF in Q2 2015 and has held it in 21 quarters since. The position peaked at $317K in Q3 2021. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • RhumbLine Advisers held 30,064 shares of Cardiff Oncology worth $39.1K as of Q2 2026.
  • RhumbLine Advisers sold 43,832 Cardiff Oncology shares in Q2 2026, an estimated $69.6K.
  • Cardiff Oncology made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3723 holding.
  • RhumbLine Advisers first reported a position in Cardiff Oncology in Q2 2015 and has held it in 21 quarters since.
  • RhumbLine Advisers's Cardiff Oncology position peaked at $317K in Q3 2021.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.